Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with ...

WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed ...

Regeneron acquires UK-based Oxular, adding ocular delivery technology and Phase II therapy OXU-001 for diabetic macular edema ...

China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK ...

One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics ...

Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that ...

Kazia Therapeutics faces a setback as the FDA deems accelerated approval for brain cancer drug paxalisib unlikely despite ...

California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo ...

It has been a year since the launch of Zepbound (tirzepatide) for obesity, and US pharma major Eli Lilly’s competition with ...

Hutchmed sells its 45% stake in SHPL for $608 million, aligning with its focus on oncology and immunology. Proceeds will fund ...

The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) ...

TJ Bio has reportedly submitted a biologics license application (BLA) to China’s Center for Drug Evaluation for GX-H9 ...